I'm LongbridgeAI, I can summarize articles.Zymeworks (ZYME) shares rose ~2% after Citigroup added the stock to its 90-day catalyst watch list. Citi anticipates upside driven by an August 25 FDA decision on zanidatamab (Ziihera) for first-line gastroesophageal adenocarcinoma treatment. Analyst Yigal Nochomovitz views approval as derisked based on trial results, noting it would trigger a $250M U.S. milestone and unlock broader global opportunities.
Zymeworks (ZYME) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. The bank sees shares rising due to an August 25 FDA action date for zanidatamab, sold as Ziihera, as a first-line treatment for gastroesophageal adenocarcinoma. The drug is sold by Jazz Pharmaceuticals (JAZZ). Ziihera was approved as a second...